Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES A LEATH

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1255313193
CMS profile
541051
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$15,484.11

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $13,885.00 8
Travel and Lodging $1,351.79 7
Food and Beverage $247.32 5

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $6,064.13 11
AbbVie Inc. $3,150.00 4
Clovis Oncology, Inc. $2,696.09 2
GlaxoSmithKline, LLC. $1,963.89 2
Seagen Inc. $1,610.00 1

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES A LEATH

NPI 1255313193 · CMS profile ID 541051

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255313193?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES A LEATH, NPI 1255313193, CMS profile ID 541051. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255313193?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHARLES A LEATH, NPI 1255313193, CMS profile ID 541051. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255313193?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHARLES A LEATH, NPI 1255313193, CMS profile ID 541051, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1255313193?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $15,484.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $12.3411/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751238043 CMS
Seagen Inc. $1,610.0009/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732464497 CMS
GlaxoSmithKline, LLC. $13.8909/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738747711 CMS
GlaxoSmithKline, LLC. $1,950.0009/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738783619 CMS
AbbVie Inc. $262.5006/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721979149 CMS
AbbVie Inc. $262.5004/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721979145 CMS
Clovis Oncology, Inc. $2,550.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722235007 CMS
AbbVie Inc. $1,968.7503/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721979141 CMS
AbbVie Inc. $656.2503/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721979137 CMS
Eisai Inc. $799.4001/31/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339605 CMS
Eisai Inc. $177.6701/31/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339607 CMS
Eisai Inc. $136.6701/31/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339609 CMS
Eisai Inc. $189.4001/31/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339611 CMS
Eisai Inc. $50.0001/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339613 CMS
Eisai Inc. $25.0001/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339615 CMS
Eisai Inc. $12.6501/31/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339617 CMS
Eisai Inc. $16.0001/31/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339693 CMS
Eisai Inc. $4,625.0001/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339695 CMS
Eisai Inc. $20.0001/31/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751346449 CMS
Clovis Oncology, Inc. $146.0901/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722230903 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,474.40 12
PY2020 $15,484.11 20
PY2021 $5,700.96 4
PY2022 $3,676.92 5
PY2023 $35,373.26 21
PY2024 $31,583.34 20
PY2025 $48,689.76 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $63,792.61 12
PY2024 Principal investigator $48,415.31 12
PY2023 Principal investigator $274,596.66 24
PY2022 Principal investigator $172,908.92 21
PY2021 Principal investigator $480,523.36 50
PY2020 Recipient $906.83 3
PY2020 Principal investigator $388,047.39 33
PY2019 Principal investigator $272,839.05 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $13,831.93 12/31/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCER No dispute reported 06/30/2026 1042502891
Principal investigator 1 Merck Sharp & Dohme LLC $3,552.10 12/31/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCER No dispute reported 06/30/2026 1042502897
Principal investigator 1 Merck Sharp & Dohme LLC $9,531.92 12/31/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent KEYNOTE-B21 , ENGOT-en11 , GOG-3053 No dispute reported 06/30/2026 1042517951
Principal investigator 1 Merck Sharp & Dohme LLC $20,173.46 12/31/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent KEYNOTE-B21 , ENGOT-en11 , GOG-3053 No dispute reported 06/30/2026 1042517965
Principal investigator 1 Merck Sharp & Dohme LLC $14,236.20 12/31/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent KEYNOTE-B21 , ENGOT-en11 , GOG-3053 No dispute reported 06/30/2026 1042517977
Principal investigator 1 Merck Sharp & Dohme LLC $106,784.96 11/28/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ARTISTRY-7 No dispute reported 06/30/2026 1042488143
Principal investigator 1 Alkermes, Inc. $5,325.00 11/14/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer No dispute reported 06/30/2026 994095875
Principal investigator 1 Alkermes, Inc. $7,765.00 11/14/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer No dispute reported 06/30/2026 994095883
Principal investigator 1 Alkermes, Inc. $480.28 10/26/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer No dispute reported 06/30/2026 994099297
Principal investigator 1 Alkermes, Inc. $27,650.00 10/17/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer No dispute reported 06/30/2026 994095649
Principal investigator 1 GlaxoSmithKline, LLC. $5,389.00 10/11/2023 Non-covered Recipient Entity
UNIV OF ALABAMA AT BIRMINGHAM
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1006146579
Principal investigator 1 Alkermes, Inc. $3,000.00 09/26/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer No dispute reported 06/30/2026 994095617
Principal investigator 1 Alkermes, Inc. $917.82 09/26/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer No dispute reported 06/30/2026 994099361
Principal investigator 1 GlaxoSmithKline, LLC. $601.20 09/18/2023 Non-covered Recipient Entity
UNIV OF ALABAMA AT BIRMINGHAM
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1006146517
Principal investigator 1 GlaxoSmithKline, LLC. $5,389.00 08/18/2023 Non-covered Recipient Entity
UNIV OF ALABAMA AT BIRMINGHAM
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1006146528
Principal investigator 1 AstraZeneca UK Limited $383.50 08/03/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
durva+monalizumab Solid Tmr-D419NC00001 Phase I/II study MEDI4736 in No dispute reported 06/30/2026 991126105
Principal investigator 1 GlaxoSmithKline, LLC. $5,389.00 05/05/2023 Non-covered Recipient Entity
UNIV OF ALABAMA AT BIRMINGHAM
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1006146537
Principal investigator 1 GlaxoSmithKline, LLC. $601.20 04/28/2023 Non-covered Recipient Entity
UNIV OF ALABAMA AT BIRMINGHAM
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1006146549
Principal investigator 1 Alkermes, Inc. $1,146.89 04/25/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer No dispute reported 06/30/2026 994097921
Principal investigator 1 AstraZeneca UK Limited $14,515.00 04/17/2023 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma No dispute reported 06/30/2026 991124611
Principal investigator 1 GlaxoSmithKline, LLC. $21,556.00 03/15/2023 Non-covered Recipient Entity
UNIV OF ALABAMA AT BIRMINGHAM
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1006146505
Principal investigator 1 GlaxoSmithKline, LLC. $601.20 01/25/2023 Non-covered Recipient Entity
UNIV OF ALABAMA AT BIRMINGHAM
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1006146569
Principal investigator 1 GlaxoSmithKline, LLC. $68.00 01/13/2023 Non-covered Recipient Entity
UNIV OF ALABAMA AT BIRMINGHAM
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1006146135
Principal investigator 1 GlaxoSmithKline, LLC. $5,708.00 01/13/2023 Non-covered Recipient Entity
UNIV OF ALABAMA AT BIRMINGHAM
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1006146559